



CLINICAL RESEARCH ARTICLE

Polygenic risk scores and the need for pharmacotherapy in neonatal abstinence syndrome

Shawana Bibi^{1,7}, Nathan Gaddis^{2,7}, Eric O. Johnson², Barry M. Lester³, Walter Kraft⁴, Rachana Singh¹, Norma Terrin⁵, Susan Adeniyi-Jones⁶ and Jonathan M. Davis^{1,5}✉

© The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc 2022

BACKGROUND: The aim of this study was to identify genetic variants associated with NAS through a genome-wide association study (GWAS) and estimate a Polygenic Risk Score (PRS) model for NAS.

METHODS: A prospective case–control study included 476 in utero opioid-exposed term neonates. A GWAS of 1000 genomes-imputed genotypes was performed to identify variants associated with need for pharmacotherapy for NAS. PRS models for estimating genetic predisposition were generated via a nested cross-validation approach using 382 neonates of European ancestry. PRS predictive ability, discrimination, and calibration were assessed.

RESULTS: Cross-ancestry GWAS identified one intergenic locus on chromosome 7 downstream of *SNX13* exhibiting genome-wide association with need for pharmacotherapy. PRS models derived from the GWAS for a subset of the European ancestry neonates reliably discriminated between need for pharmacotherapy using *cis* variant effect sizes within validation sets of European and African American ancestry neonates. PRS were less effective when applying variant effect sizes across datasets and in calibration analyses.

CONCLUSIONS: GWAS has the potential to identify genetic loci associated with need for pharmacotherapy for NAS and enable development of clinically predictive PRS models. Larger GWAS with additional ancestries are needed to confirm the observed *SNX13* association and the accuracy of PRS in NAS risk prediction models.

Pediatric Research (2023) 93:1368–1374; <https://doi.org/10.1038/s41390-022-02243-0>

IMPACT:

- Genetic associations appear to be important in neonatal abstinence syndrome.
- This is the first genome-wide association in neonates with neonatal abstinence syndrome.
- Polygenic risk scores can be developed examining single-nucleotide polymorphisms across the entire genome.
- Polygenic risk scores were higher in neonates receiving pharmacotherapy for treatment of their neonatal abstinence syndrome.
- Future studies with larger cohorts are needed to better delineate these genetic associations.

INTRODUCTION

Neonatal abstinence syndrome (NAS) is a constellation of signs of withdrawal in the neonate from in utero exposure to maternal opioids.^{1,2} The incidence of NAS has exponentially increased over the past decade, concurrent with the global opioid epidemic.³ NAS has a highly variable expression, making accurate prediction of the need for pharmacotherapy a significant challenge.⁴ Opioid exposed neonates are monitored in the hospital several days for signs indicating the need for pharmacotherapy.^{5–7}

Despite decades of research, accurate prediction of NAS expression remains elusive. Recent studies have utilized maternal and neonatal factors associated with NAS expression and developed predictive models.^{8,9} Genetic factors explain some variation and have been associated with opioid use disorder

(OUD) in adults. Genetic variation in opioid receptor genes and genes involved in opioid metabolism are associated with variable response to pharmacotherapy.^{10–14}

The objective of this study was to identify genetic variants associated with the need for pharmacotherapy of NAS through a genome-wide association study (GWAS) and establish polygenic risk score (PRS) models to enhance prediction of need for treatment.

METHODS**Patient population and phenotype**

Subjects were recruited from four prospective studies—two clinical trials and two observational cohort studies.^{15,16} The 8-site clinical trial compared

¹Division of Newborn Medicine, Tufts Medical Center, Boston, MA, USA. ²RTI International, Research Triangle Park, NC, USA. ³Department of Pediatrics, Alpert Medical School of Brown University and Women and Infants Hospital, Providence, RI, USA. ⁴Division of Clinical Pharmacology, Thomas Jefferson University, Philadelphia, PA, USA. ⁵Tufts Clinical and Translational Science Institute, Tufts School of Graduate Biomedical Sciences, Boston, MA, USA. ⁶Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA, USA. ⁷These authors contributed equally: Shawana Bibi, Nathan Gaddis. ✉email: jdavis@tuftsmedicalcenter.org

Received: 15 April 2022 Revised: 9 June 2022 Accepted: 24 July 2022

Published online: 16 August 2022

methadone with morphine for the treatment of NAS. An observational arm of this trial included: (1) neonates whose parents consented for the trial but who did not require treatment; (2) parents who did not consent for randomization in the trial but agreed to data collection and genetic analyses.¹⁵ Additional neonates were recruited from a single-center trial of sublingual buprenorphine for NAS and an observational study led by Thomas Jefferson University.¹⁶

Inclusion criteria for these studies included neonates born > 36 weeks gestational age to mothers with known OUD in medication assisted treatment programs. All neonates were monitored in hospital for a minimum 3–5 days prior to discharge home. Pharmacotherapy for NAS was based on Finnegan Scoring criteria per clinical trial and observational study protocols.^{15–17} Control neonates met all inclusion criteria, but did not require pharmacotherapy. Neonates were excluded if they did not meet inclusion criteria, were one of a multiple birth, had major congenital abnormalities, died or left the hospital before day 5. Institutional Review Boards at each center approved the studies and informed consent was obtained.

DNA isolation, genotyping, and quality control

Genomic DNA was extracted from buccal swabs using previously published methodologies.¹⁸ All subjects were genotyped with the Infinium Omni2.5–8v1.3 array which contains probes for ~2.4 million SNPs. Subjects were assigned to ancestral groups (African American (AA), European American (EA)) based on comparison to the HapMap CEU, YRI, and CHB populations using STRUCTURE and ancestral outliers were removed.^{19,20} SNP- and subject-level quality control (QC) were conducted using PLINK.²¹ SNPs with missing call rate >10% or Hardy–Weinberg p value <0.0001 were removed and heterozygous haploid SNPs were set to missing. Subject-level QC removed subjects with missing call rate >10%, duplicates, first degree relatives (identity-by-descent π -hat >0.4), cryptically related subjects (identity-by-state distance >0.9), and subjects with excessive homozygosity. Following genotype QC, 94 AAs (2,328,444 SNPs) and 394 EAs (2,325,421 SNPs) remained.

To expand genomic coverage, genotype imputation was performed with the Michigan Imputation Server using 1000 Genomes (1000G) Phase 3 (Version 5) reference panel.²² After removing variants with minor allele frequency (MAF) < 0.01 in the reference (1000G AFR for AAs, 1000G EUR for EAs) or study populations or with imputation R_{sq} < 0.8, ~13.4 million, and ~8.5 million SNPs and indels remained in AAs and EAs, respectively.

Genome-wide association analyses

Genome-wide variant associations with the need for pharmacotherapy were calculated separately for AA ($N = 94$) and EA ($N = 382$) neonates with non-missing phenotypes and covariates using RVtests software, adjusting for sex and genetic principal components as covariates.²³ Results for association testing of AA and EA neonates were combined via inverse variance-weighted meta-analysis using METAL software with genomic control.²⁴ Results were filtered to eliminate variants with MAF < 0.01 and imputation quality < 0.8. Gene associations with need for pharmacotherapy were generated from the GWAS summary statistics using the MAGMA software.²⁵

Nested cross-validation for PRS development

Due to small sample size, a nested cross-validation approach was used to develop PRS models for predicting need for pharmacologic treatment (Supplemental Fig. 1). Given the small number of AA neonates and the differing genetic architecture of AAs and EAs, only EA neonates were used for PRS model development. Subjects were divided into training and validation sets, with neonates from Thomas Jefferson University ($N = 92$, ~25% of overall cohort) assigned to the validation set, establishing independent training and validation sets.

For cross-validation, the training set ($N = 290$) was divided into 5 equal sets with similar case:control ratios. Each was used as the target population in 5 separate runs of PRSice-2 utilizing the classic PRS calculation approach of clumping and thresholding (Supplemental Fig. 1).²⁶ The remaining 80% of the training set was used as the base population for PRSice-2. In preparation for running PRSice-2, genome-wide association testing was run in the base population with RVtests, adjusting for sex and genetic principal components as covariates. For the PRSice-2 analyses, the 1000 Genomes EUR group was used to improve LD estimation for clumping (MAF cutoff 0.01). Each PRSice2 analysis generated an optimal PRS model consisting of different sets of variants.

Validation of PRS models from cross-validation

Results from cross-validation were combined for testing in the reserved Jefferson validation set and in AA neonates using different intersections of the variant sets from the optimal PRS models. Specifically, PRS models consisting of variants present in 1, 2, 3, 4, or all 5 optimal models were tested for their discriminative and predictive abilities in the validation set. Two distinct approaches were used to assess PRS model performance, differing in the source of variant effect sizes used to calculate PRS: (1) the *cis* approach, which calculates PRS as the average sum of validation set effect sizes weighted by validation set allele dosages for PRS model variants, and (2) the *trans* approach, which calculates PRS as the average sum of training set effect sizes weighted by validation set dosages for PRS model variants. For both approaches, the dosages of variants with negative effect sizes were first inverted and the sign of the effect sizes were changed to positive. The predictive and discriminatory ability of different variant sets was assessed using analysis of variance (ANOVA) and area under the receiver operating characteristic curve (AUROC) statistics. The five PRS models were tested for their discriminative and predictive abilities in AA neonates using similar methodology.

Calibration of PRS models

Calibration of PRS models was performed as described previously.²⁷ Optimal PRS thresholds for discriminating need for pharmacotherapy for NAS were calculated by maximizing the Youden-Index based on kernel smoothed densities using the `oc_youden_kernel` function of the `cutpointr` package. Mean calibration of PRS models was tested by comparing the average predicted need for treatment based on the PRS threshold to the actual overall rate. PRS and thresholds were calculated using the effect sizes from the training set for the Jefferson EA validation set or the full EA set (training + validation) for AAs. Weak calibration of PRS models (not overestimating/underestimating predicted outcome) was assessed by calculating the calibration intercept and slope and examining their deviation from 0 and 1.

RESULTS

GWAS meta-analysis of need for pharmacotherapy

Cross-ancestry GWAS meta-analysis in AA (cases = 59, controls = 35) and EA (cases = 231, controls = 151) neonates identified one intergenic locus on chromosome 7 between the *LINC02889* and *SNX13* genes exhibiting genome-wide significant association with need for pharmacotherapy ($p = 4.22 \times 10^{-8}$ for top variant rs73313786; Fig. 1—Manhattan plot; Supplemental Fig. 2—QQ plot; Supplemental Fig. 3—LocusZoom plots; Supplemental Table 1—variants with $p < 0.001$). A second intergenic locus on chromosome 6 between the *LOC107986667* and *MEAT6* genes achieved near-genome-wide significance ($p = 5.48 \times 10^{-8}$ for top variant rs1566002; Supplemental Fig. 4—LocusZoom plots). Ancestry-specific GWAS revealed no genome-wide significant loci for AA (Supplemental Fig. 5 and Supplemental Table 2). However, the same genome-wide significant chromosome 7 intergenic locus observed in the cross-ancestry meta was observed for EA ancestry alone ($p = 2.17 \times 10^{-8}$ for top variant rs10277501; Supplemental Fig. 6 and Supplemental Table 3).

Prior studies identified 7 variants in the *OPRM1*, *COMT*, *OPRD1*, *OPRK1*, and *PNOC* genes associated with NAS (need for pharmacologic treatment, treatment with ≥ 2 medications, length of hospital stay).^{28,29} None of the previously identified variants extended to need for NAS treatment in our GWAS based on a Bonferroni-corrected p value of 0.007 (0.05/7 SNPs) (Table 1). However, rs2614095 (intronic variant within *PNOC*) was nominally significant in the present study ($p = 0.042$) and showed the same direction of affect across studies (minor allele A being protective). Although no variants in the *OPRM1* gene approached genome-wide significance, the top variant rs641457 had a $\beta = 0.7117$ and $p = 0.0037$. This occurred despite different primary outcomes in the various studies (e.g., need for NAS treatment in the present study).

Analysis of gene-based association with the need for pharmacotherapy from the GWAS failed to identify any significant cross-




Fig. 1 Manhattan plot of cross-ancestry GWAS of need for pharmacotherapy for NAS. Genome-wide variant associations with need for pharmacotherapy for NAS were calculated separately for AA ($N = 94$) and EA ($N = 382$), adjusting for sex and genetic principal components as covariates. Association testing results for AA and EA neonates were combined via inverse variance-weighted meta-analysis with genomic control. Results were filtered to eliminate variants with $MAF < 0.01$ and imputation quality < 0.8 . One locus on chromosome 7 downstream of *SNX13* achieved genome-wide significance.

ancestry or ancestry-specific associations (based on Bonferroni-corrected p value threshold of 2.74×10^{-6} for 18,229 genes; Supplemental Tables 4–6).

PRS development for predicting the need for pharmacotherapy for NAS

The overall sample was split into a training set (non-Jefferson samples; $N = 290$) and a validation set (Jefferson samples; $N = 92$). Due to small sample size, AA neonates were reserved for validation of PRS models in a different ancestry. New sets of variants for PRS calculation were established based on the number of times a variant occurred in the 5 optimal PRS models from a nested cross-validation approach. This approach resulted in variant sets ranging in size from 1126 (present in all 5 optimal PRS models) to 383,754 (present in 1 of the optimal PRS models) (Supplemental Table 7a–e).

Analysis of discriminatory and predictive performance of PRS models in EA neonates

ANOVA and AUROC on five sets of variants confirmed that all PRS models demonstrated excellent discriminatory and predictive performance for the need for pharmacotherapy in the training set (Supplemental Table 8 and boxplots in Supplemental Fig. 7).

All variant sets could effectively discriminate between neonates requiring pharmacotherapy and those not needing it in the EA validation set when using *cis* effect sizes derived from the validation set to calculate PRS, but not when using *trans* effect sizes from the training set (Table 2 and Supplemental Figs. 8 and 9). In the *cis* analysis, PRS models performed well, improving with increasing size of variant set (ANOVA from 1.62×10^{-08} for the smallest set to 4.34×10^{-48} for the largest; AUROCs ranging from 0.813 to 1.000). In the *trans* context (often used in clinical settings), performance of the PRS models was worse. No model detected significant differences between treated/untreated neonates (maximum AUROC 0.61).

Analysis of discriminatory and predictive performance of PRS models in AA neonates

PRS suffer from lack of portability across ancestries due to different linkage disequilibrium patterns and allele frequencies.³⁰ Two approaches to assess performance in AAs were used: one where *cis* effect sizes from testing among AAs were used for PRS calculation and the other where *trans* effect sizes were derived from the full EA dataset (training + validation). All 5 PRS variant sets performed well distinguishing between treated and untreated AA neonates when AA effect sizes were used (Table 2; Supplemental Fig. 10). PRS performance improved with increasing variant set size, with p values ranging from 2.98×10^{-06} for the smallest set to 1.05×10^{-38} for the largest and AUROCs ranging from 0.768 to 0.998. Performance of the PRS models in the second approach where EA effect sizes were used for calculation of PRS (Table 2; Supplemental Fig. 11) was comparable to the EA validation set (Table 2). Two variant sets resulted in significant differences between treated and untreated AA neonates with corresponding AUROCs of 0.62. Unlike the first approach, PRS performance did not improve with increasing variant size.

Calibration of PRS models for prediction of need for pharmacotherapy in EA and AA neonates

For the EA validation set, the smallest set of variants most closely recapitulated the actual treatment rate, with others not performing as well (Table 3). For AA neonates, all variant sets resulted in a predicted treatment rate of zero based on the EA-based cut point, which likely reflects differing allele frequencies between EAs and AAs (Table 3). To assess “weak calibration,” the calibration intercept (target value = 0) and slope (target value = 1) were calculated for each PRS model. For EA, all PRS models had negative intercepts, indicative of overestimation of treatment risk (Table 3). The PRS models for the 2 smallest variant sets had calibration slopes > 1 , suggesting that estimates of treatment risk

Table 1. Variants previously associated with NAS severity phenotypes.

SNP	Phenotype	Gene	Minor allele	Previous studies		This study (phenotype = NAS treatment)					
				OR	p value	AA		EA		AA + EA	
						OR	p value	OR	p value	OR	p value
rs1799971	LOS	OPRM1	G	-6.9	0.02	NA	NA	0.806	0.362	0.806	0.363
rs204076	≥2 Meds	OPRD1	A	2.8	0.04	0.630	0.261	0.785	0.136	0.766	0.083
rs2614095	≥2 Meds	OPRD1	A	6.6	0.008	0.787	0.566	0.722	0.043	0.730	0.042
rs351776	LOS	PNOC	A	0.3	0.01	1.548	0.251	1.222	0.212	1.263	0.128
rs4732636	≥2 Meds	PNOC	A	-4.7	0.04	0.890	0.796	1.217	0.258	1.173	0.342
	NAS treatment	PNOC	A	2.2	0.05						
	NAS treatment	PNOC	A	4.2	0.05						
	≥2 Meds	PNOC	A	2	0.04						
	LOS	PNOC	A	3.8	0.004						
	LOS	PNOC	A	5.8	0.01						
rs702764	≥2 Meds	OPRK1	C	4.1	0.003	1.433	0.327	1.299	0.210	1.328	0.133
rs740603	NAS treatment	COMT	A	0.4	0.01	0.767	0.441	1.063	0.704	1.008	0.956
	≥2 Meds	COMT	A	1.9	0.02						
	LOS	COMT	A	5.3	0.01						

were too moderate. Conversely, the PRS models based on the 3 largest variant sets had calibration slopes <1, suggesting that estimates of treatment risk were too extreme (Table 3). For the AA neonates, the calibration intercepts for all models were close to the target value of 0, but the calibration slopes were all >1 suggestive of estimates that were too moderate (Table 3).

DISCUSSION

Being able to predict NAS expression would provide crucial information to guide treatment decisions and optimize NAS outcomes. Advances in the fields of genetics/genomics and computational biology have generated immense interest in including genomic information in predictive models. In this first-of-its-kind GWAS of neonates with in utero opioid exposure, a genomic locus was identified upstream of the *SNX13* gene that was associated with need for pharmacotherapy. PRS models that segregate neonates by their need for therapy were then developed. These findings may lead to a better understanding of NAS and provide a new tool to assist in predicting the need for pharmacotherapy of NAS. Further development of PRS in larger samples in concert with clinical data may permit a precision medicine approach.

Our multi-ancestry GWAS identified a single intergenic locus ~124 kb downstream of *SNX13* with genome-wide significance with need for pharmacotherapy. *SNX13* is a sorting nexin and G protein regulator involved in intracellular trafficking that has been implicated in heart failure and associated with neutrophil counts, high-density lipoprotein cholesterol level, apolipoprotein A1 level, and mean platelet volume.^{31–35} *SNX13* is expressed in numerous tissues, including the brain, which is particularly relevant to addiction, where expression is highest in the cerebellum.³⁶ Although there is no previous evidence of *SNX13* being implicated in addiction, a related sorting nexin, *SNX27*, has been implicated in attenuating response to cocaine in mice, possibly through regulation of neuron excitability.^{28,37} Further studies using larger datasets are needed to establish whether the association with the locus near *SNX13* is reproducible and whether *SNX13* expression is regulated by the locus.

Our findings did not find a definitive association of *OPRM1* with NAS pharmacotherapy by GWAS. Prior adult studies identified variants in the *OPRM1* gene associated with opioid addiction.^{12,29} Wachman et al. described variants in *OPRM1* associated with decreased length of stay (LOS) and need for pharmacotherapy.¹³ Genes involved in the dopamine pathway (e.g., Catechol-O-Methyltransferase (*COMT*)) and *PNOC* (Prepronociceptin) were also found to be associated with LOS and need for pharmacotherapy.³⁸ In a larger replication cohort of 199 mother–infant dyads, some variant associations did not meet significance threshold after correction for multiple comparison testing.³⁹ In the current study ($N=476$), none of the seven previously associated candidate variants were associated with need for NAS treatment after a Bonferroni correction for multiple testing. However, rs2614095, an intronic variant within *PNOC*, was nominally significant ($p=0.042$). The minor allele A was protective in previous studies and the current study.

Recent studies have consistently noted the importance of maternal ancestry in NAS, with non-Hispanic whites displaying higher risk compared to other ancestries.^{40,41} Our study included non-Hispanic whites and a smaller number of AAs, which allowed us to capture some of the ancestral diversity for NAS. Although there was a mixture of ancestry-specific and cross-ancestry associations, the small sample size makes it impossible to draw any definitive conclusions about the interaction of ancestry and genetic loci relative to NAS. Future studies should focus on larger cohorts with greater representation of other ancestries.

PRS holds great promise for assessing an individual's risk of a disease or trait, how well an individual will respond to specific

Table 2. ANOVA and AUROC analyses of PRS model performance in EA and AA validation sets.

Target set	Effect size source	Variant set	N variants	N samples	ANOVA p	AUROC (95% CI)
EA validation set	EA validation set	1/5 CVs	382,872	92	4.34E-48	1 (NA, NA)
		2/5 CVs	90,954	92	4.93E-45	1 (NA, NA)
		3/5 CVs	28,013	92	7.14E-40	1 (NA, NA)
		4/5 CVs	7043	92	6.64E-26	0.985 (0.965, 1)
		5/5 CVs	1126	92	1.62E-08	0.814 (0.726, 0.902)
EA validation set	EA training set	1/5 CVs	382,872	92	0.987	0.479 (0.354, 0.605)
		2/5 CVs	90,954	92	0.565	0.543 (0.418, 0.668)
		3/5 CVs	28,013	92	0.905	0.512 (0.391, 0.633)
		4/5 CVs	7043	92	0.364	0.552 (0.432, 0.673)
		5/5 CVs	1126	92	0.123	0.606 (0.485, 0.727)
AA validation set	AA validation set	1/5 CVs	356,467	94	1.05E-38	0.998 (0.994, 1)
		2/5 CVs	85,217	94	1.58E-38	0.999 (0.997, 1)
		3/5 CVs	26,334	94	2.46E-30	0.994 (0.985, 1)
		4/5 CVs	6721	94	2.84E-19	0.958 (0.923, 0.993)
		5/5 CVs	1097	92	2.98E-06	0.768 (0.669, 0.868)
AA validation set	EA full set	1/5 CVs	356,467	93	0.2	0.596 (0.471, 0)
		2/5 CVs	85,217	94	0.034	0.624 (0.506, 0)
		3/5 CVs	26,334	94	0.074	0.599 (0.48, 0)
		4/5 CVs	6721	93	0.281	0.569 (0.447, 0)
		5/5 CVs	1097	93	0.024	0.622 (0.502, 0)

Table 3. PRS model calibration in EA and AA validation sets.

Target set	Effect size/cut point source set	Variant set	Optimal cut point	Actual prevalence	PRS prevalence	Intercept	Slope
EA validation	EA training	1/5 CVs	0.836	0.587	0.880	-0.489	-0.990
		2/5 CVs	1.077	0.587	1.000	-0.746	-15.426
		3/5 CVs	1.222	0.587	0.989	-0.902	-1.652
		4/5 CVs	1.229	0.587	0.783	-0.899	6.589
		5/5 CVs	1.352	0.587	0.630	-1.031	3.958
AA validation	EA full	1/5 CVs	0.725	0.628	0.000	0.029	109.181
		2/5 CVs	0.988	0.628	0.000	-0.130	75.514
		3/5 CVs	1.071	0.628	0.000	-0.215	38.727
		4/5 CVs	1.159	0.628	0.000	-0.267	9.136
		5/5 CVs	1.451	0.628	0.000	-0.436	6.014

therapies, and other factors influenced by genetic predisposition. PRS models for predicting pharmacotherapy of NAS were developed in EAs using nested cross-validation and tested in EA and AA validation sets. Although PRS performance was consistent between EAs and AAs, it was highly dependent on the source of effect sizes for PRS calculation. PRS calculated using *cis* effect sizes from validation sets demonstrated excellent discrimination between neonates needing/not needing pharmacotherapy. However, PRS using *trans* effect sizes did not perform as well. The differences in performance likely resulted from variability in effect sizes due to small sample size or perhaps some model overfitting. The weak discrimination when using *trans* effect sizes has implications for utility in clinical settings. Similarly, calibration analyses suggest that current PRS models have not been sufficiently powered to justify clinical use. However, the excellent performance of PRS models for discriminating the need for pharmacotherapy in independent cohorts using *cis* effect sizes suggests that these models do hold promise and could be effective with increased sample sizes and higher ancestral diversity.

While our data provide evidence supporting the potential benefit of using PRS in the management of NAS, there are some limitations. The sample size in this study was small for a GWAS, limiting the power to discover loci with small effect sizes. However, our nested cross-validation approach and establishment of largely independent validation sets allowed us to make optimal use of the samples that were available. Also, the need-for-treatment phenotype relied on Finnegan Scoring criteria which can be subjective, limit phenotypic variability, and further reduce power. Unfortunately, collecting samples sufficiently powered for GWAS of NAS is extremely difficult, as evidenced by the 5 years required to assemble the cohort used in this study. Another limitation is the relatively small representation of non-EA ancestries, which is particularly problematic due to the potential for substantially different causal genetic architectures among different ancestries resulting from variation in allele effect sizes and linkage disequilibrium patterns.⁴² In fact, recent studies have demonstrated poor trans-ancestry portability of both GWAS findings and PRS.^{43,44} Given that the majority of genetic studies have been conducted with participants of European ancestry, the

clinical applicability of these findings to individuals of non-European ancestry is limited, which exacerbates healthcare disparities.³⁰ Strengthening regulatory protections against genetic discrimination, open sharing of GWAS summary statistics, and equitable investment in global populations and ancestries are critical next steps for studies of NAS and other diseases and traits.

REFERENCES

- MacMillan, K. D. Neonatal abstinence syndrome: review of epidemiology, care models, and current understanding of outcomes. *Clin. Perinatol.* **46**, 817–822 (2019).
- Grossman, M. & Berkwitz, A. Neonatal abstinence syndrome. *Semin. Perinatol.* **43**, 173–186 (2019).
- U.S. Agency for Healthcare and Quality (AHRQ). Trends in neonatal abstinence syndrome births in the United States. https://www.hcup-us.ahrq.gov/reports/Trends_NeonatalAbstinenceSyndrome_Births_UnitedStates.pdf (2019).
- Jansson, L. M. & Patrick, S. W. Neonatal abstinence syndrome. *Pediatr. Clin. North Am.* **66**, 353–367 (2019).
- Devlin, L. A. & Davis, J. M. A practical approach to neonatal opiate withdrawal syndrome. *Am. J. Perinatol.* **35**, 324–330 (2018).
- Patrick, S. W. et al. Neonatal opioid withdrawal syndrome. *Pediatrics* **146**, e2020029074 (2020).
- Winkelman, T. N. A. et al. Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004–2014. *Pediatrics* **141**, e20173520 (2018).
- Singh, R. et al. Predictors of pharmacologic therapy for neonatal opioid withdrawal syndrome: a retrospective analysis of a statewide database. *J. Perinatol.* **41**, 1381–1388 (2021).
- Patrick, S. W. et al. Development and validation of a model to predict neonatal abstinence syndrome. *J. Pediatr.* **229**, 154–160 (2021).
- Kendler, K. S. et al. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. *Arch. Gen. Psychiatry.* **57**, 261–269 (2000).
- Goldman, D., Oroszi, G. & Ducci, F. The genetics of addictions: uncovering the genes. *Nat. Rev. Genet.* **6**, 521–532 (2005).
- Smith, A. H. et al. Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. *Mol. Psychiatry* **22**, 346–352 (2017).
- Wachman, E. M. et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. *JAMA* **309**, 1821–1827 (2013).
- Wachman, E. M. & Farrer, L. A. The genetics and epigenetics of neonatal abstinence syndrome. *Semin. Fetal Neonatal Med.* **24**, 105–110 (2019).
- Davis, J. M. et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. *JAMA Pediatr.* **172**, 741–748 (2018).
- Kraft, W. K. et al. Buprenorphine for the treatment of the neonatal abstinence syndrome. *N. Engl. J. Med.* **376**, 2341–2348 (2017).
- Kaltenbach, K. & Jones, H. E. Neonatal abstinence syndrome: presentation and treatment considerations. *J. Addict. Med.* **10**, 217–223 (2016).
- <https://www.dnagenotek.com/US/support/protocols/oragene-discover.html>. Accessed Sep 30 2021.
- Frazer, K. A. et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**, 851–861 (2007).
- Falush, D., Stephens, M. & Pritchard, J. K. Inference of population structure using multilocus genotype data: dominant markers and null alleles. *Mol. Ecol. Notes* **7**, 574–578 (2007).
- Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
- Das, S. et al. Next-generation genotype imputation service and methods. *Nat. Genet.* **48**, 1284–1287 (2016).
- Zhan, X. et al. RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data. *Bioinformatics* **32**, 1423–1426 (2016).
- Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- de Leeuw, C. et al. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).
- Choi, S. W. & O'Reilly, P. F. PRSice-2: Polygenic Risk Score software for biobank-scale data. *Gigascience* **8**, giz082 (2019).
- Van Calster, B. et al. 'Evaluating diagnostic tests and prediction models' of the STRATOS initiative. Calibration: the Achilles heel of predictive analytics. *BMC Med.* **17**, 230 (2019).
- Rifkin, R. A. et al. GIRK currents in VTA dopamine neurons control the sensitivity of mice to cocaine-induced locomotor sensitization. *Proc. Natl Acad. Sci. USA* **115**, E9479–E9488 (2018).
- Bauer, I. E., Soares, J. C. & Nielsen, D. A. The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: a systematic review. *Am. J. Addict.* **24**, 15–23 (2015).
- Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat. Genet.* **51**, 584 (2019).
- Li, J. et al. SNX13 reduction mediates heart failure through degradative sorting of apoptosis repressor with caspase recruitment domain. *Nat. Commun.* **5**, 5177 (2014).
- Chen, M. H. et al. Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. *Cell* **182**, 1198–1213 (2020).
- Vuckovic, D. et al. The polygenic and monogenic basis of blood traits and diseases. *Cell* **182**, 1214–1231 (2020).
- Willer, C. J. et al. Discovery and refinement of loci associated with lipid levels. *Nat. Genet.* **45**, 1274–1283 (2013).
- Richardson, T. G. et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. *PLoS Med.* **17**, e1003062 (2020).
- Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–585 (2013).
- Munoz, M. B. & Slesinger, P. A. Sorting nexin 27 regulation of G protein-gated inwardly rectifying K⁺ channels attenuates in vivo cocaine response. *Neuron* **82**, 659–669 (2014).
- Wachman, E. M. et al. Variations in opioid receptor genes in neonatal abstinence syndrome. *Drug Alcohol Depend.* **155**, 253–259 (2015).
- Wachman, E. M. et al. Association of maternal and infant variants in PNOC and COMT genes with neonatal abstinence syndrome severity. *Am. J. Addict.* **26**, 42–49 (2017).
- Parikh, A. et al. Racial association and pharmacotherapy in neonatal opioid withdrawal syndrome. *J. Perinatol.* **39**, 1370–1376 (2019).
- Brown, S. E. et al. Association of race and ethnicity with withdrawal symptoms, attrition, opioid use, and side-effects during buprenorphine therapy. *J. Ethn. Subst. Abuse.* **9**, 106–114 (2010).
- Galinsky, K. J. et al. Estimating cross-population genetic correlations of causal effect sizes. *Genet. Epidemiol.* **43**, 180–188 (2019).
- Vilhjálmsdóttir, et al. Modeling linkage disequilibrium increases accuracy of polygenic risk scores. *Am. J. Hum. Genet.* **97**, 576–592 (2015).
- Lam, M. et al. Comparative genetic architectures of schizophrenia in East Asian and European populations. *Nat. Genet.* **51**, 1670–1678 (2019).

ACKNOWLEDGEMENTS

The authors want to thank: Adam Czyski, Erica Oliveira—Brown, Mark Hudak—Jacksonville, Jeffrey Shenberger—Baystate Medical Center, Peter Marro—Maine Medical Center, Elisha Wachman—Boston Medical Center, Barbara Engelhardt—Vanderbilt, Debra Bogen—University of Pittsburgh, and Michelle Ehrlich—Mt. Sinai.

AUTHOR CONTRIBUTIONS

All authors were involved with the planning, conduct, analyses, interpretation, and writing of the study; W.K., S.A.-J., B.M.L., and J.M.D. were involved in patient recruitment for the study.

FUNDING

This study was funded by the National Institute of Drug Abuse (NIDA) R01DA032889, R21DA041706-02 (to J.M.D., B.M.L.), NIDA R01DA02976 (to W.K.), and Charles H. Hood Foundation (to J.M.D.).

COMPETING INTERESTS

The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Informed consent was required.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41390-022-02243-0>.

Correspondence and requests for materials should be addressed to Jonathan M. Davis.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.